Seattle Genetics, Inc. (Nasdaq: SGEN) reported data from its ongoing clinical trials of SGN-40 in multiple myeloma and non-Hodgkin's lymphoma at the American Society of Hematology (ASH) 2005 Annual Meeting being held in Atlanta December 10-13. Data from these phase I studies demonstrate that SGN-40 is well tolerated and has antitumor activity. In the non-Hodgkin's lymphoma study, objective responses were observed following one cycle of SGN-40 therapy. Dose escalation is continuing in both trials.
